Mary Caffrey

CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology community warns of financial threats from the Inflation Reduction Act. Updates reflect late Tuesday release of the proposed 2026 schedule for the Hospital Outpatient Prospective Payment System.

Artificial intelligence (AI) transforms oncology by enhancing clinical decision-making, improving patient outcomes, and shaping future health care training, as discussed by experts at Tennessee Oncology's “Tech Innovations in Community Oncology."

During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining operations, while addressing challenges in data accuracy and equity, said speakers at the Tennessee Oncology “Tech Innovations in Community Oncology."

Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage cancer care over time. A feature from our upcoming special issue of Evidence-Based Oncology: our annual ASCO recap.

Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.

Coverage from IVBM Princeton, held May 8, 2025.

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell transplant or CAR T-cell therapy.

New Jersey Attorney General Matthew Platkin said the question before the court is whether First Choice Women's Resource Centers can ignore a subpoena amid a state consumer fraud investigation.

A prior settlement of $6 billion was rejected because it would have shielded the Sackler family from lawsuits even from parties who were not part of the agreement.

A global surge in rheumatoid arthritis with local hotspots highlights the need for targeted public health interventions.

New data shed light on the best strategies for managing patients who develop interstitial lung disease (ILD) while being treated with trastuzumab deruxtecan. City of Hope will host a virtual breast cancer forum to review key studies presented at ASCO.

A post-hoc analysis of EPCORE-NHL-1 was presented at ASCO.

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, discusses the potential consequences of losing free health care screening coverage.

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50. Obesity is among the factors linked to rising rates of cancer in young adults.

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, shares how one mobile health care initiative is addressing critical barriers to medical access for underserved populations.

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.

MATTERHORN offers another case of moving immunotherapy from metastatic to early-stage cancers.

Today, cancer stage and tumor size tell which patients will receive adjuvant chemotherapy. But the rise of biomarker testing and artificial intelligence could offer new tools for assessing risk.

An ASCO session on quality services shows how patient and caregiver engagement is crucial to gain better outcomes and cost savings from symptom monitoring efforts.

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer (TNBC) and estrogen receptor–positive tumors.

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven therapies, revolutionizing cancer treatment and diagnostics.

Following former President Joe Biden's diagnosis with metastatic prostate cancer, news coverage has focused on his lack of prostate-specific antigen (PSA) screening over the past decade.